GLP‐1RA vs placebo
All‐cause mortality · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
- Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes onlyOR 0.88 [0.82, 0.95]7 studies · 46393 participantsHigh